Furthermore, we found that gefitinib treatment led to lower levels of phosphorylated EGFR, but the levels of NSUN2 expression were maintained in all five NSCLC patients with intrinsic resistance to gefitinib (Fig. 1f, g). This evidence concerns the gene EGFR and non-small cell lung carcinoma.